Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Bozena Cybulska-Stopa

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

B. Cybulska-Stopa1, K. Regulski2, R. Wiśniowski3, M. Rajczykowski4, R. Suwinski5, M. Domagała-Haduch1, K. Piejko1, A.P. Drosik1, I. Bar-Letkiewicz6, L. Rauch2, T. Szczęsny7, M. Ziobro1, J. Mackiewicz6

Author affiliations

  • 1 Clinical Oncology Department, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Cracov Branch, 31-115 - Krakow/PL
  • 2 Katedra Informatyki Stosowanej I Modelowania, Akademia Górniczo-Hutnicza, 30-054 - Kraków/PL
  • 3 Oddział Onkologii I Hematologii,, Beskidzkie Centrum Onkologii, 43-382 - Bielsko-Biała/PL
  • 4 Ii Klinika Radioterapii Ichemioterapii, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 31-115 - Gliwice/PL
  • 5 Ii Klinika Radioterapii I Chemioterapii, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL
  • 6 Oddział Onkologii Klinicznej I Doświadczalnej, Uniwersytet Medyczny w Poznaniu, Poznań/PL
  • 7 Maria Sklodowska-curie Institute - Oncology Center, Warsaw., Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, 02-781 - Warsaw/PL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4309

Background

Previous studies showed that high and low body mass index (BMI) is associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI is associated with worse prognosis in metastatic CRC (mCRC). Whether BMI is a prognostic or predictive factor in patients with mCRC is unclear. The aim of the study was to assess the efficacy outcomes according to BMI range in patients with mCRC treated with bevacizumab plus FOLFOX (oxaliplatin, 5-fluorouracyl, folinic acid) chemotherapy regimen.

Methods

The analysis included patients with mCRC receiving bevacizumab plus FOLFOX in the second line treatment. Patients were divided into three study groups according to BMI range: >30 kg/m2 (obese patients), ≥ 25 - < 30 kg/m2 (overweight patients), <25 (normal weight patients). The median PFS (progression-free survival) and OS (overall survival) of the treated patients was compared based on the BMI range. Analysis of Kaplan-Meier survival, univariate ANOVA, chi-squared tests for categorical variables were used. Analysis of variance (ANOVA) was used to determining the significance of impact on quantitative variables, while for qualitative variables chi-squared tests were used to compare patient from different BMI groups.

Results

The study included 237 patients with mCRC. The median age of the patients was 65 years (range 34–82). The study group included 54% of males. The median OS and PFS in the study group was 14.6 and 8.8 months, respectively. The comparison of obese vs overweight vs normal BMI range patients revealed a significant difference in mOS (17.5 vs 14.3 vs 13.1 months, p = 0.01) and mPFS (9.4 vs 9.1 vs 7.3 months, p = 0.03). The regression analysis (Pearson’s linear correlation) also confirmed that there is a statistically significant relationship between the length of OS and PFS and the BMI value. Higher BMI was associated with a better prognosis. The location of the primary lesion on the left side of the colon, less than two metastatic sites and CEA within the normal range before start of the treatment was linked with statistically longer OS.

Conclusions

Obese and overweight patients presented longer OS and PFS compared with normal weight patients with mCRC cancer treated with bevacizumab plus FOLFOX chemotherapy regimen.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.